Work

Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792)

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx365.005

Authors: M.L. Telli, S. Lord, E. Dean, V. Abramson, H-T. Arkenau, C. Becerra, S.M. Tolaney, R. Tang, M.S. Penney, J. Pollard, G. Conboy, S.Z. Fields, G. Shapiro

Institutions: Stanford Medicine, Stanford University, Churchill Hospital, University of Oxford, The Christie Hospital, The Christie NHS Foundation Trust, Vanderbilt University Medical Center, Sarah Cannon Research Institute, Dana-Farber Cancer Institute, Vertex Pharmaceuticals (United States), Vertex Pharmaceuticals (United Kingdom)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Syndax Pharmaceuticals, Ipsen, Daiichi Sankyo Europe

OpenAlex ID: W2763899732

FWCI: 0.121

Cites:

Cited by: 3

Related to: 10